3-Deoxy-3-acetyl abiraterone-3-ene
It is susceptible to hydrolysis by esterases and is an orally active inhibitor of the steroidal enzyme CYP17A1 that is used in the treatment of prostate cancer.
Additional information on 3-Deoxy-3-acetyl abiraterone-3-ene
Catalogue No.
VE006955
CAS No.
N/A
Molecular Formula
C26H31NO
Molecular Weight
373.5
Parent drug
Abiraterone
IUPAC Name
1-[17-(Pyridin-3-yl)androsta-3, 5, 16-trien-3-yl]ethanone
Synonyms
N/A
References
Goldberg, Tamara, and Evangelina Berrios-Colon. “Abiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer.” Pharmacy and Therapeutics, vol. 38, no. 1, 1 Jan. 2013, pp. 23–26, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628169/. Accessed 31 Jan. 2022.
Status
In-stock
